Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical…
This section is Partnership Content ProvidedThe content in this section has been provided by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Globe…